[2] Retatrutide review NIH / PMC
Over that period, people taking GLP-1 medications were found to be 16 percent less likely to develop epilepsy than those using DPP-4 inhibitors, even after researchers adjusted for factors such as age, high blood pressure and cardiovascular disease
Now, Let's Talk GLP-1s: The Game-Changers in Weight Management This brings us to the medications that are truly reshaping the conversation around weight and metabolic health in 2026: GLP-1 receptor agonists
Never Miss a Story Sign up to get our BEST stories of the week straight to your inbox
Peptides, Cognitive Protection, & Brain Aging with Dr
Frequency of administration In the case wherein the patient's condition does not improve, upon the doctor's discretion the administration of the compounds is administered chronically, that is, for an extended period of time, including throughout the duration of the patient's life in order to ameliorate or otherwise control or limit the symptoms of the patient's disease or condition
